Feb 18, 2022 · Post-transplant lymphoproliferative disorders (PTLD) are commonly CD20 + and rarely CD20 − . Co-expression of mesenchymal/muscle markers is unusual in PTLD and non-PTLD lymphomas . The main clinical differential diagnosis is the manifestation of a post-transplant smooth muscle tumour (PTSMT) [3, 4].

Posttransplant lymphoproliferative disorder (PTLD) is a rare lymphoid and/or plasmocytic proliferation that occurs after allogeneic hematopoietic stem cell transplantation (allo-HSCT). We aimed to identify the pathologic features and clinical outcomes of T-cell PTLD, an extremely rare subtype of PTLD, after allo-HSCT.

In this case report, we describe a patient with PTLD with features intermediate between PBL and PBM, with clinical features more consistent with PBL, and with an excellent response to a daratumumab-based regimen.

May 7, 2013 · Immunohistochemical studies were performed using an avidin-biotin-peroxidase complex method on an automated immunostainer (Ventana, Tucson, AZ, USA), using antibodies against CD3, CD15, CD30, CD43, CD79a (Ventana), CD5, CD45, ALK-1 (Biocare, Concord, CA, USA), and CD138 (Serotec, Raleigh, NC, USA).

May 17, 2010 · Aberrant expression of CD20 or CD79a by neoplastic T-cells can lead to a mistaken diagnosis of B cell PTLD, and cases expressing CD30 and EBV can mimic CHL type PTLD. A clonal proliferation of T-large granular lymphocytes has been reported in solid organ transplants ( Sabnani et al , 2006 ), but this is thought to be due to chronic antigen ...

See reference case "Plasmacytoma-Like PTLD, EBV+" for details.

We report a case of a 63-year-old man who developed 2 metachronous Epstein-Barr virus-related PTLDs beginning 10 years after heart transplantation. A polymorphic B-cell PTLD developed first that completely regressed after immunosuppressive therapy was partially with-drawn. Then, a monomorphic T-cell PTLD developed 31 months later.

May 9, 2024 · B cell markers BOB1, OCT2, CD79a are more commonly expressed in the large neoplastic cells of classic Hodgkin lymphoma PTLD versus classic Hodgkin lymphoma in immunocompetent hosts (100%, 86% and 50% compared with 6%, 14% and 10%, respectively) (Expert Opin Ther Targets 2009;13:1137)

CD20/CD79a/PAX5/CD3-negative post-transplant lymphoma with aberrant actin and desmin co-expression-a potential differential diagnostic pitfall between PTLD and PTSMT Ann Hematol . 2022 Apr;101(4):881-883. doi: 10.1007/s00277-021-04394-2.

In most monomorphic PTLD, the sheets of large, atypical lymphocytes are B-cells that express CD19, CD20, CD79a, and often EBV-LMP1 and EBNA2. Aberrant expression of CD43 and CD45RO may be present, and occasional cases may show expression of CD30.